Breaking Finance News

Zacks Investment Research downgraded Mirna Therapeutics Inc (NASDAQ:MIRN) to Hold in a report released today.

Just yesterday Mirna Therapeutics Inc (NASDAQ:MIRN) traded 4.26% lower at $3.38. Mirna Therapeutics Inc’s 50-day average is $3.45 and its two hundred day moving average is $4.18. With the last stock price down 46.22% relative to the 200-day average, compared with the S&P 500 which has fallen -0.01% over the same time period. Trading volume was was up over the average, with 30,902 shares of MIRN changing hands over the typical 20,559 shares..

Zacks Investment Research has downgraded Mirna Therapeutics Inc(NASDAQ:MIRN) to Hold in a report released 8/18/2016.

Performance Chart:

Mirna Therapeutics Inc (NASDAQ:MIRN)

A total of 4 analysts have reported on MIRN. Three analysts rate the stock a strong buy, one firm rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the company to underperform, and lastly 0 firmsrate the stock as sell with an average target stock price of $11.00

Mirna Therapeutics Inc has a 52 week low of $2.23 and a 52 week high of $11.01 . MIRN’s market capitalization is presently $0.0.

About Mirna Therapeutics Inc (NASDAQ:MIRN)

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, and miR-16 and let-7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.